As the Biden administration leans into the Cancer Moonshot 2.0, the life sciences industry has the opportunity to launch a new era of precision oncology. How can we accelerate progress toward truly personalized medicine and revolutionize cancer care?
Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.
Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.
The election results sent biopharma stock soaring. Breaking down what’s really on tap for biopharma over the next four years.
Through this series of infographics, learn how payers, providers, and life sciences companies will be impacted by our 45th president.
